COH04S1

Last updated

COH04S1
Vaccine description
Target SARS-CoV-2
Vaccine type Viral vector
Clinical data
Routes of
administration
Intramuscular
Identifiers
CAS Number

COH04S1 is a covid vaccine developed by the City of Hope Medical Center. This vaccine targets patients who are immunocompromised; immunocompromised patients have often shown a weak antibody response to past COVID-19 vaccines. COH04S1 is also targeted on people who are at a high risk of COVID-19 complications. The City of Hope Medical Center strives to make a better option than the current EUA and FDA approved vaccines, which are not working as well on this group of individuals.

Contents

The group leading the investigation of the vaccine is led by scientists named Felix Wussow with a Ph.D., Flavia Chiuppesi with a Ph.D. as well, them both City of Hope assistant research professors in the Department of Hematology & Hematopoietic Cell Transplantation. The leader is named Don J. Diamond, Ph.D.: professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope. The vaccine is the first to study the safety and effectiveness in patients that have received a bone marrow transplant or chimeric antigen receptor therapy. It is also the first to look at the differences between the Pfizer vaccine with one that accommodates people who are receiving immunosuppressive therapy.

Previous COVID-19 vaccines in blood cancer patients show a high probability that 1 out of 4 blood cancer patients fail to produce antibodies. COH04S1 hopes to lower the chances of failure in producing antibodies in blood cancer patients.

This vaccine is built on a FDA-approved platform known as modified vaccinia ankara, also known as MVA. This platform has famously been used safely worldwide and effectively in cancer and transplant patients.

Phase 1 Trial

The vaccine has presently passed a phase 1 trial with healthy volunteers between the ages of 18 and 55 who have not had COVID-19. The vaccine aims to make the immune system produce antibodies as well as make the body produce T cells that provide long-term protection against future outbreaks. They first developed a MVA delivery vehicle, to keep the genetic components for a compound at a molecular level. SARS-CoV-2 and nucleocapsid proteins were injected into the platform for it to replicate DNA within cells, which would trigger the strong reproduction of T cells as well as potent antibodies against the virus. MVA vaccines are proven to produce an immune response within 14 days with only mild side effects.

The trial patients would have received two shots with 28 days in between, not knowing whether either of them were placebos or not.

Phase 2 Trial

COH04S1 is currently the only COVID-19 vaccine to pass onto phase 2 trials in cancer patients. This vaccine does not grow or reproduce in the human body, making it fit for stem cell transplant and CAR T patients. The volunteers will be closely monitored soon after the trial as well as a check up a year after the trial.

City of Hope accepted blood cancer patients who received a bone marrow transplant, or a CAR T cell therapy at least three months before volunteering, as well as meeting other requirements.

Related Research Articles

Aplastic anemia (AA) is a severe hematologic condition in which the body fails to make blood cells in sufficient numbers. Blood cells are produced in the bone marrow by stem cells that reside there. Aplastic anemia causes a deficiency of all blood cell types: red blood cells, white blood cells, and platelets.

<span class="mw-page-title-main">Multiple myeloma</span> Cancer of plasma cells

Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. Often, no symptoms are noticed initially. As it progresses, bone pain, anemia, renal insufficiency, and infections may occur. Complications may include hypercalcemia and amyloidosis.

<span class="mw-page-title-main">Chronic myelogenous leukemia</span> Medical condition

Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a cancer of the white blood cells. It is a form of leukemia characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. CML is a clonal bone marrow stem cell disorder in which a proliferation of mature granulocytes and their precursors is found; characteristic increase in basophils is clinically relevant. It is a type of myeloproliferative neoplasm associated with a characteristic chromosomal translocation called the Philadelphia chromosome.

<span class="mw-page-title-main">Hematopoietic stem cell transplantation</span> Medical procedure to replace blood or immune stem cells

Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood, in order to replicate inside a patient and produce additional normal blood cells. HSCT may be autologous, syngeneic, or allogeneic.

<span class="mw-page-title-main">Graft-versus-host disease</span> Medical condition

Graft-versus-host disease (GvHD) is a syndrome, characterized by inflammation in different organs. GvHD is commonly associated with bone marrow transplants and stem cell transplants.

<span class="mw-page-title-main">Gemtuzumab ozogamicin</span> Pharmaceutical drug

Gemtuzumab ozogamicin, sold under the brand name Mylotarg®, is an antibody-drug conjugate that is used to treat acute myeloid leukemia (AML).

Stem-cell therapy uses stem cells to treat or prevent a disease or condition. As of 2024, the only FDA-approved therapy using stem cells is hematopoietic stem cell transplantation. This usually takes the form of a bone marrow or peripheral blood stem cell transplantation, but the cells can also be derived from umbilical cord blood. Research is underway to develop various sources for stem cells as well as to apply stem-cell treatments for neurodegenerative diseases and conditions such as diabetes and heart disease.

<span class="mw-page-title-main">Monoclonal antibody therapy</span> Form of immunotherapy

Monoclonal antibodies (mAbs) have varied therapeutic uses. It is possible to create a mAb that binds specifically to almost any extracellular target, such as cell surface proteins and cytokines. They can be used to render their target ineffective, to induce a specific cell signal, to cause the immune system to attack specific cells, or to bring a drug to a specific cell type.

<i>Human betaherpesvirus 5</i> Species of virus

Human betaherpesvirus 5, also called human cytomegalovirus (HCMV,HHV-5), is a species of virus in the genus Cytomegalovirus, which in turn is a member of the viral family known as Herpesviridae or herpesviruses. It is also commonly called CMV. Within Herpesviridae, HCMV belongs to the Betaherpesvirinae subfamily, which also includes cytomegaloviruses from other mammals. CMV is a double-stranded DNA virus.

A Cytomegalovirus vaccine is a vaccine to prevent cytomegalovirus (CMV) infection or curb virus re-activation in persons already infected. Challenges in developing a vaccine include adeptness of CMV in evading the immune system and limited animal models. As of 2018 no such vaccine exists, although a number of vaccine candidates are under investigation. They include recombinant protein, live attenuated, DNA and other vaccines.

<span class="mw-page-title-main">Daratumumab</span> Monoclonal antibody

Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38, which is overexpressed in multiple myeloma cells. Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.

<span class="mw-page-title-main">Pluri Inc.</span> Israeli biotechnology company

Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.

<span class="mw-page-title-main">HIV/AIDS research</span> Field of immunology research

HIV/AIDS research includes all medical research that attempts to prevent, treat, or cure HIV/AIDS, as well as fundamental research about the nature of HIV as an infectious agent and AIDS as the disease caused by HIV.

<span class="mw-page-title-main">Roland Mertelsmann</span>

Roland Mertelsmann is a German hematologist and oncologist. He was a professor at the Freiburg University Medical Center, Department of Internal Medicine I (Oncology/Hematology). Mertelsmann is known for his scientific works in the fields of hematology, oncology, gene therapy and stem cell transplantation.

David G. Maloney is an oncologist and researcher at Fred Hutchinson Cancer Research Center and the University of Washington who specializes in developing targeted immunotherapies for the treatment of blood cancers.

<span class="mw-page-title-main">Shimon Slavin</span> Israeli professor of medicine

Shimon Slavin is an Israeli professor of medicine. He pioneered immunotherapy mediated by allogeneic donor lymphocytes and innovative methods for stem cell transplantation to cure hematological malignancies and solid tumors. He also used hematopoietic stem cells to induce transplantation tolerance to bone marrow and organ allografts.

<span class="mw-page-title-main">Selinexor</span> Anti-cancer drug

Selinexor sold under the brand name Xpovio among others, is a selective inhibitor of nuclear export used as an anti-cancer medication. It works by blocking the action of exportin 1 and thus blocking the transport of several proteins involved in cancer-cell growth from the cell nucleus to the cytoplasm, which ultimately arrests the cell cycle and leads to apoptosis. It is the first drug with this mechanism of action.

<span class="mw-page-title-main">Nirali N. Shah</span> American physician-scientist and pediatric hematologist-oncologist

Nirali N. Shah is an American physician-scientist and pediatric hematologist-oncologist, serving as head of the hematologic malignancies section of the pediatric oncology branch at the National Cancer Institute. She researches the translation of immunotherapeutic approaches to treat high-risk hematologic malignancies in children, adolescents and young adults.

Stephanie J. Lee is an American haematologist and physician scientist who is professor and associate director at the Fred Hutchinson Cancer Research Center. Lee works to improve the lives of blood stem cell transplant and bone marrow patients by better understanding the chronic form of graft-versus-host disease. Lee is the former president of the American Society of Hematology.

<span class="mw-page-title-main">Cynthia E. Dunbar</span> American hematologist

Cynthia Dunbar is an American scientist and hematologist at the National Heart Lung and Blood Institute (NHLBI), which is part of the National Institutes of Health (NIH). She is the Branch Chief of the Translational Stem Cell Biology Branch.

References

  1. "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).

Marquez L (11 May 2022). "Phase 2 Trial Opens for City of Hope's Novel COVID-19 Vaccine". City of Hope. Retrieved 18 May 2022.